FDA Approves Gilead’s Bixlenvo (Bictegravir/Lenacapavir) as Smallest Once-Daily Single-Tablet Regimen for Complex HIV Cases

FDA Approves Gilead’s Bixlenvo (Bictegravir/Lenacapavir) as Smallest Once-Daily Single-Tablet Regimen for Complex HIV Cases

On August 27, 2026, the U.S. Food and Drug Administration (FDA) approved Gilead Sciences’ Bixlenvo™ (bictegravir 75 mg / lenacapavir 50 mg), marking a major milestone in HIV therapy. Bixlenvo is the smallest once-daily single-tablet regimen (STR) available and represents the first and only STR option for virologically suppressed adults on complex multi-pill regimens who cannot take standard once-daily therapies due to pre-existing drug resistance or tolerability challenges.

Novel Mechanism and Dosing Simplification

Bixlenvo combines two potent mechanisms of action:

1. Bictegravir (75 mg): A guideline-recommended integrase strand transfer inhibitor (INSTI) with a high genetic barrier to resistance.
2. Lenacapavir (50 mg): A first-in-class capsid inhibitor with a multi-stage mechanism and no known cross-resistance to other existing antiretroviral classes.

This combination is specifically tailored for patients who have successfully achieved viral suppression but remain on highly complex, multi-tablet regimens. By consolidating these therapies into a single daily pill, Bixlenvo significantly reduces the pill burden and simplifies long-term treatment.¹

Strong Phase III Clinical Foundation

The FDA's decision is supported by robust data from two pivotal Phase III trials, ARTISTRY-1 (NCT05502341) and ARTISTRY-2 (NCT06333808). Topline 48-week results, which were presented during late-breaker sessions at the 33rd Conference on Retroviruses and Opportunistic Infections (CROI 2026), demonstrated that:

• Switching to Bixlenvo maintained high rates of virological suppression (HIV-1 RNA < 50 copies/mL) that were highly comparable to patients' baseline complex multi-tablet regimens or standard Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide).
• The single-tablet combination was generally well-tolerated, with a safety profile consistent with its individual components and no new safety signals.

Clinical and Academic Commentary

Leading infectious disease experts highlighted the critical clinical gap that Bixlenvo addresses. According to Dr. Chloe Orkin, lead investigator of the ARTISTRY-1 trial:

"Bixlenvo offers a new once-daily STR designed for the evolving needs of people with HIV. The approval is a significant advancement in HIV treatment, especially for individuals unable to benefit from guideline-recommended STRs due to challenges like pre-existing resistance or tolerability. It expands tailored, simplified dosing to people whose needs were not fully met by existing single tablet therapies."